Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPAHCT: AV-101 in Pulmonary Arterial Hypertension
2023-508734-34-00Phase 3Completed
- Sponsor
- Aerovate Therapeutics
- Start
- Mar 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing AV-101 with Placebo (2 arms). Primary endpoints: Placebo-corrected change from baseline at Week 24 in pulmonary vascular resistance (PVR) and Placebo-corrected change from baseline at Week 24 in 6-minute walk distance (6MWD). Started Mar 2024; status: completed.
02
Drugs
4-chlorokynurenine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2023-508734-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508734-34-00.